pCPA Update as of November 30, 2017

December 8, 2017
-

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update

 

The November 30, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are:

  • Four new drug products have initiated pCPA negotiations, for a total of 39 active negotiations;
  • Eleven negotiations have been completed/closed, for a total of 188 joint completed/closed negotiations; and
  • One new drug product was added to the “No pCPA Negotiations” list, for a total of 56 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level.

In addition to the information above, MORSE Consulting is tracking the number of products reviewed by CADTH that have yet to initiate negotiations with the pCPA – which we refer to as “under pCPA Consideration”. The latest update since September 30, 2017 is:

  • Six new drug products have received recent CDEC or pERC recommendations, for a total of approximately 23 products under pCPA Consideration

Please see below for more details.

Negotiation Initiation

  • Four new drug products have initiated pCPA negotiations since the last update, for a total of 39 active negotiations
Brand Name
Generic Name
Manufacturer
Indication
Recommendation/
Notification to Implement Date
Time to Negotiation*
(days)
Cerdelga
Eliglustat Sanofi Genzyme Gaucher Disease July 26, 2017 112 days
 

Cerezyme
Imiglucerase Sanofi Genzyme Gaucher Disease N/A N/A
 

Elelyso
taliglucerase alfa Pfizer Canada Inc. Gaucher Disease October 28, 2015 749 days
 

VPRIV
Velaglucerase Shire Human Genetic Therapies Gaucher Disease April 25, 2011 2396 days

*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation

Signal De-coded

Presumably due to the July 2017 recommendation for Cerdelga, the pCPA appears to have initiated a class negotiation of some therapies used to treat Gaucher’s Disease by opening negotiations on existing therapies, including Elelyso which was given a “do not list” recommendation in Oct 2015. 

Negotiations Completed

  • Eleven negotiations have been completed/closed since the last update, for a total of 188 joint completed/closed negotiations.
    • Nine negotiations were completed:
Brand Name
Generic Name
Manufacturer
Indication
Negotiation Initiation
Duration * (days)
Afinitor**
Everolimus Sandoz Canada Inc. Neuroendocrine tumours of gastrointestinal or lung origin March, 2017 184 days
Giotrif

(second letter of intent)

Afatinib Boehringer Ingelheim Canada Ltd. Non-small cell lung cancer July, 2017 123 days
Keytruda
Pembrolizumab Merck Canada Inc. Non-small cell lung cancer (second line or beyond) January, 2017 304 days
Keytruda
Pembrolizumab Merck Canada Inc. Non-small cell lung cancer (first line) September, 2017 61 days
Metoject
Methotrexate Medexus Rheumatoid Arthritis June, 2016 518 days
Nucala
Mepolizumab GlaxoSmithKline Inc. Severe eosinophilic asthma October, 2016 396 days
Opdivo
Nivolumab Bristol-Myers Squibb Canada Squamous cell carcinoma of the head and neck (SCCHN) September, 2017 61 days
Pheburane
Sodium phenylbutyrate Medunik Canada Urea cycle disorders April, 2017 214 days
Stivarga

(second letter of intent)

Regorafenib Bayer Inc. Metastatic and/or unresectable gastrointestinal stromal tumours August, 2017 92 days

 ** Note: negotiation was completed in September 2017

    • Two negotiations were closed:
Brand Name
Generic Name
Manufacturer
Indication
Negotiation Initiation
Duration *
(days)
Brilinta
Ticagrelor AstraZeneca Canada Inc. prevention of atherothrombotic events with history of myocardial infraction August, 2017 92 days
Methadose
Methadone Mallinckrodt Canada ULC Opioid Dependence July, 2017 123 days

*Approximation: Negotiation initiation and end date assumed to be mid-month for the purposes of the calculation

Signal De-coded

Of note, the pCPA has completed negotiations for Nucala, while negotiations for Xolair and Cinquair are still ongoing in the severe asthma treatment space. 

No pCPA Negotiation

  • One new drug product was added to the “No pCPA Negotiations” list, for a total of 56 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level
Brand Name
Generic Name
Manufacturer
Indication
Recommendation/
Notification to Implement Date
CADTH Recommendation
Time to decision*
(days)
Tafinlar and Mekinist
(dabrafenib and trametinib) Novartis Pharmaceuticals Canada Inc. Non-small cell lung cancer November 17, 2017 Do NOT reimburse 0

*Approximation: decision date assumed to be mid-month for the purposes of the calculation

Based on information collected by MORSE Consulting:

  • Six new drug products received a CDEC or pERC recommendation or notification to implement since the last update, for a total of approximately 23 products under pCPA Consideration.
Brand Name
Generic Name
Manufacturer
Indication
Final Recommendation/Notification to Implement
Adlyxine
lixisenatide Sanofi-aventis Canada Inc. Diabetes mellitus, Type 2 November 23, 2017
Fibristal
ulipristal acetate Allergan Inc. Uterine fibroids (signs and symptoms) November 22, 2017
Repatha
evolocumab Amgen Canada Primary hyperlipidemia and mixed dyslipidemia November 22, 2017
Rexulti
Brexpiprazole Otsuka-Lundbeck Schizophrenia November 22, 2017
Ocrevus
ocrelizumab Hoffman-La Roche Limited Multiple Sclerosis, relapsing November 21, 2017
Tresiba
insulin degludec Novo Nordisk Canada Diabetes mellitus (type 1 and 2) November 20, 2017

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share